Detalhe da pesquisa
1.
A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance.
Clin Cancer Res
; 29(5): 888-898, 2023 03 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36342102
2.
Durable response of anaplastic thyroid carcinoma to FS118, a bispecific LAG-3/PD-L1 antibody, after checkpoint inhibitor progression: a case report.
J Immunother Cancer
; 10(10)2022 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-36202556
3.
A phase I safety and pharmacologic study of a twice weekly dosing regimen of the oral taxane BMS-275183.
Clin Cancer Res
; 13(13): 3906-12, 2007 Jul 01.
Artigo
Inglês
| MEDLINE | ID: mdl-17606724
4.
Gemcitabine and epirubicin in patients with metastatic breast cancer: a phase I/II study.
Breast
; 15(5): 601-9, 2006 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-17045160
5.
Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial.
Clin Cancer Res
; 11(2 Pt 1): 690-6, 2005 Jan 15.
Artigo
Inglês
| MEDLINE | ID: mdl-15701857
6.
PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
Lung Cancer
; 80(2): 216-22, 2013 May.
Artigo
Inglês
| MEDLINE | ID: mdl-23410825